tradingkey.logo

Digital therapeutics platform DarioHealth Q2 revenue falls steeper-than-expected 14%

ReutersAug 12, 2025 10:41 AM


Overview

  • DarioHealth Q2 2025 revenue fell 14% yr/yr to $5.4 mln, missing expectations

  • Operating loss for Q2 narrowed by 43% yr/yr due to operational efficiencies

  • Co secured $5 mln new CARR, with $53 mln pipeline of opportunities


Outlook

  • Dario expects cashflow breakeven by end of 2026 to early 2027

  • Company anticipates $53 mln in commercial opportunities pipeline

  • AI-driven efficiencies to cut operating expenses by 15% in 12-15 months


Result Drivers

  • REVENUE DECLINE - Co attributes revenue decline to shift from one-time revenues to building ARR and delays in onboarding new clients

  • GROSS MARGIN IMPROVEMENT - Gross margin increased to 55% from 44% yr/yr due to changes in revenue mix and lower amortization expenses

  • OPERATING EFFICIENCIES - Operating expenses decreased by 36% yr/yr due to AI-driven process optimizations and post-merger integration activities


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

$5.40 mln

$6.91 mln (3 Analysts)

Q2 Net Income

Miss

-$12.99 mln

-$10.80 mln (3 Analysts)

Q2 Operating Income

Miss

-$9.20 mln

-$8.72 mln (2 Analysts)

Q2 Gross Profit

$3 mln

Q2 Operating Expenses

$12.20 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for DarioHealth Corp is $2.25, about 77.6% above its August 11 closing price of $0.50

Press Release: ID:nPn8nWzC9a

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI